Article
A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing.
Journal of clinical laboratory analysis - 1 Jun 2018
Jia Shiyu, Zhang Rui, Lin Guigao, Peng Rongxue, Gao Peng, Han Yanxi, Fu Yu, Ding Jiansheng, Wu Qisheng, Zhang Kuo, Xie Jiehong, Li Jinming
Abstract excerpt
BACKGROUND: KRAS mutations are the key indicator for EGFR monoclonal antibody-targeted therapy and acquired drug resistance, and their accurate detection is critical to the clinical decision-making of colorectal cancer. However, no proper quality control material is available for the current detection methods, particularly next-generation sequencing (NGS). The ideal quality control material for NGS needs to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.